Reviva reports 40% enrollment in Phase 3 schizophrenia trial; top-line data expected mid-2023

REVIVA PHARMACEUTICALS HOLDINGS, INC.

About 40% of patients treated in pivotal Phase 3 RECOVER trial of brilaroxazine; no treatment-related SAEs.
Top-line data from Phase 3 trial expected mid-2023; NDA submission planned if positive, potential commercial launch in 2025.
Completed DDI study for brilaroxazine; results indicate advantage over other antipsychotics regarding drug interactions.
Raised $8.5M in September 2022 from registered direct offering and private placement; improved financial position.
Exploring non-dilutive financing and partnerships to expand brilaroxazine into bipolar, MDD, ADHD, PAH, IPF; combined market >$70B.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.